NCT02603055View on ClinicalTrials.gov

A Clinical Trial to Evaluate a Recombinant Hepatitis E Vaccine in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

April 30, 2016

Study Completion Date

August 31, 2016

Conditions
Hepatitis E
Interventions
BIOLOGICAL

30μg/0.5ml Hepatitis E vaccine

three doses, 30μg/0.5ml per dose

BIOLOGICAL

30μg/0.5ml Recombinant Hepatitis E vaccine

30μg/0.5ml Hepatitis E vaccine developed by Xiamen innovax biotech Co.,Ltd.,three doses, 30μg/0.5ml per dose

Trial Locations (1)

210009

Jiangsu Provincial Center for Diseases Control and Prevention, Nanjing

All Listed Sponsors
collaborator

Changchun Institute of Biological Products Co., Ltd.

INDUSTRY

lead

Jiangsu Province Centers for Disease Control and Prevention

NETWORK

NCT02603055 - A Clinical Trial to Evaluate a Recombinant Hepatitis E Vaccine in Healthy Adults | Biotech Hunter | Biotech Hunter